JPRN-UMIN000012296已完成未知
Phase II trial of carbon-ion radiotherapy with Gemcitabine for locally advanced pancreatic cancer (GUNMA1301) - Carbon-ion radiotherapy with Gemcitabine for locally advanced pancreatic cancer (GUNMA1301)
Gunma University Heavy Ion Medical Center0 个研究点目标入组 21 人开始时间: 2013年11月14日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 21
研究概览
简要总结
MST=16.5M Overall survival 1y 69%, 2y 23% Local control 1y 93%, 2y 72% In favorable group (CA19-9 <1000, D95>52.8G), Overall survival 1y 84%, 2y 47% Local control 1y 100%, 2y 76% MST 22.2M
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Past history of irradiation to the target region 2) Infection around the target 3) Metalic stent at the bile duct 4) Pleural effusions or ascites 5) Past history of chemotherapy within 4 weeks before start of this treatment 6) Uncontrolled severe complication 7) Active ulcer of stomach or duodenum 8) Active double cancers 9) Interstitial pneumonia 10) In pregnancy or during the lactation preiod 11) Other medical or psychological unsuitable reasons
研究者
相似试验
已完成
不适用
Carbon-ion radiotherapy for Cholangiocarcinoma: A multi-institutional study by the Japan Carbon-ion radiation oncology group (J-CROS)CholangiocarcinomaJPRN-UMIN000035565Gunma University Heavy Ion Medical center56
已完成
不适用
Carbon ion radiotherapy for stage I non-small cell lung cancerclinical stage I non-small cell lung cancerJPRN-UMIN000003797Gunma University Heavy Ion Medical Center37
招募中
2 期
A Phase II Trial of 4 fractions of CIRT for Intermediate-risk Prostate CancerD011471Prostate cancerJPRN-jRCT1032220391Ishikawa Hitoshi212
招募中
2 期
Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RPCancer of ProstateNCT03899077Cancer Research Antwerp202
已完成
不适用
Feasibility study of Carbon-Ion Radiotherapy for Re-Irradiation of Locoregionally Recurrent Head and Neck Tumorsrecurrent head and neck tumorsJPRN-UMIN000033862Hospital of the National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Sciences and Technology48